Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

Metastatic Castration-resistant Prostate Cancer Clinical Trial

Official title:

Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05116579
• Other study ID #: 2021-FXY-171
• Status: Recruiting
• Start date: October 31, 2021
• Est. completion date: August 31, 2023

Study information

• Verified date: November 2021
• Source: Sun Yat-sen University
• Contact: Yonghong Li, M.D.
• Phone: +020-87343656
• Email: liyongh[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

To evaluate the application value of customized ctDNA monitoring in efficacy assessment and prediction during PARPi treatment

Description:

This clinical study is an open-label, single-center, observational study to evaluate the application value of customized ctDNA monitoring in efficacy assessment and prediction during PARPi treatment in mCRPC patients. A total of 30 participants with second-line treatment failure will be registered in this study. Whole blood collection will be conducted during the treatment for ctDNA detection, homologous recombination repair (HRR) genes testing, personalized panel customization and whole exome sequencing.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: August 31, 2023
• Est. primary completion date: March 31, 2023
• Gender: Male
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

Patients must meet ALL of the following criteria:

1. Willing and able to provide informed consent.

2. Adult males from 18 to 75 years age.

3. History of histologically or cytologically confirmed adenocarcinoma of the prostate with DDR genes mutation (BRCA1/2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L) detected by high throughput sequencing

4. Documented evidence of metastatic castration resistant prostate cancer (mCRPC) and proposed treatment of PARP inhibitors.

5. Evidence of measurable target lesion in imaging studies.

6. Participants can provide adequate formalin fixed paraffin-embedded (FFPE) tumor tissue collected before any treatment: tumor cell content>30% and necrotic cells<10%.

7. ECOG performance status 0-1

8. Estimated survival=12 weeks Exclusion Criteria:

Patients must NOT meet any of the following criteria:

1. Do not meet the inclusion criteria.

2. Under any other anti-tumor therapy like chemotherapy and/or immunotherapy.

3. Receiving organ transplantation in the last 3 months.

4. Participants with autoimmune diseases or history of HBV, HCV or HIV infection (acute or chronic).

5. Participants with pneumonia.

6. Severe concurrent illness or co-morbid disease that would make the subject unsuitable for enrolment

7. Unwilling and unable to provide informed consent.

8. Patients who are judged unsuitable for clinical trial participation by the investigators. Elimination Criteria: Violation of the prescribed rule of medication that may influence the judgment of curative effect and safety.

Related Conditions & MeSH terms

• Metastatic Castration-resistant Prostate Cancer
• Prostatic Neoplasms

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radiological progression free survival (rPFS)	Radiological progression free survival (rPFS) - defined as the time from randomisation to radiological progression, assessed by investigator per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 (soft tissue) and Prostate Cancer Working Group-3 (PCWG-3) criteria (bone), or death from any cause, or the last follow-up, whichever occurs first	From date of randomisation to until radiographic progression (up to 1 year)
Primary	Objective Response Rate (ORR)	ORR is the percentage of patients with at least one visit response of Complete response (CR) or Partial response (PR), in their soft tissue disease assessed by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), in the absence of progression on bone scan assessed by Prostate Cancer Working Group 3 (PCWG3)). Per RECIST v1.1, CR=Disappearance of all target lesions; PR = >=30% decrease in the sum of diameters of target lesions; For each treatment group, ORR is the number of patients with a CR and PR.	From randomisation until radiographic progression (up to 1 year)
Primary	PSA response rate	PSA response rate is defined as the proportion of patients with a PSA decline (defined as a =30%, =50% and other declines in PSA from baseline).	From randomisation until radiographic progression (up to 1 year)
Secondary	Overall Survival (OS)	OS is defined as time from treatment commencement to death of any cause	2 years